Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced yesterday that the U.S. Food and Drug Administration (FDA) has approved the bispecific antibody emicizumab (US product name: HEMLIBRA®) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with Hemophilia A (congenital Factor Viii deficiency) with factor VIII inhibitors. This […]
The post Chugai’s HEMLIBRA® Receives the World’s First Regulatory Approval from FDA for Hemophilia A with Inhibitors appeared first on Biotechin.Asia.
This post first appeared on Biotechin.asia – Your Daily Biotech And Healthca, please read the originial post: here
